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lymphoma in a patient with psoriatic arthritis
treated with etanercept
To the Editor: Primary thyroid marginal zone B-cell
lymphoma is a very rare type of lymphoma that
usually develops in patients with autoimmune
thyroiditis.1 There are previous reports of diffuse
large B-cell lymphoma and several subtypes of T-cell
lymphomas possibly associated with etanercept,2,3
but marginal zone B-cell lymphoma in the thyroid is
not reported to our knowledge. We present a rare
case of primary thyroid marginal zone B-cell lym-
phoma in a patient with psoriasis and psoriatic
arthritis using etanercept for 4 years.
A 58-year-old woman presented with a rapidly
growing mass on the front of her neck. Twenty-six
years previously, she was given the diagnosis of
psoriasis based on the presence of erythematous
scaly plaques on her entire body. Despite treatmentFig 1. Primary thyroid marginal zone B-cell
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Open access under CC BY-NC-ND license.with methotrexate (MTX), cyclosporine, and photo-
therapy, skin lesions and arthralgia of the hand and
foot persisted. She was referred to the rheumatology
department and given the diagnosis of psoriatic
arthritis based on classification criteria for psoriatic
arthritis (CASPAR) criteria. She received etanercept
(50 mg per week) in combination with MTX (10 mg
per week) for 4 years. Her skin lesions and arthralgia
improved over time, and nomajor adverse event was
noted in association with the etanercept use.
Neck computed tomography revealed a diffuse
enlargement of the thyroid gland. Her thyroid-
stimulating hormone level was elevated at 14.11
mIU/mL (normal, 0.32-5.00 mIU/mL) and other thy-
roid function values were within normal ranges. No
evidence of autoimmune thyroiditis was observed.
Thyroid fine-needle aspiration revealed polymor-
phous lymphocytes and a few atypical lymphocytes.
The patient underwent a right hemithyroidectomy for
a suspected thyroid lymphoid neoplasm. The final
pathology on the surgical specimen showed dense
lymphoid infiltrate containing multiple lymphoid
follicles with germinal centers. The tumor cell
consisted of centrocyte-like cells, small lymphocytes,
plasma cells, and scattered eosinophils (Fig 1, A).
They were positive for CD20, B-cell lymphoma
(BCL)-2, and kappa and lambda light chain but no
expression of CD3, CD10, and BCL-6, and the
germinal centers were highlighted with CD21. She
was given the diagnosis of low-grade B-cell
lymphoma consistent with marginal zone B-cell
lymphoma. She then discontinued etanercept and
MTX and received 3 cycles of adjuvant chemotherapy
with rituximab, cyclophosphamide, vincristine, and
prednisolone and 36 Gy total of radiotherapy. No
evidenceof lymphomaprogressionwasdetectedover
12 months. However, 2 weeks after cessation oflymphoma. Dense infiltration of mixed
eosinophils, plasma cells, and large cells
t normal structures of the thyroid gland (A);
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Letters e153etanercept, she experienced aggravation of the
psoriasis and psoriatic arthritis but refused other
treatments except nonsteroidal anti-inflammatory
drugs and topical betamethasone/calcipotriol.
Tumor necrosis factor (TNF)-alfa receptor
blockers are great advances in the treatment of
psoriasis and psoriatic arthritis. The immune
regulation of TNF-alfa has been highly controversial
regarding its risk in carcinogenesis. Kimball et al4
recently reported that there was little difference in
rates of lymphomas among different treatment
methods such as nonbiologic systemics, etanercept,
other TNF-alfa receptor blockers, and phototherapy.
To our knowledge, no reports have shown an
increased risk of lymphoma in patients using
etanercept.5 However, in patients with chronic
inflammatory disease and a history of long-term
use of immunosuppressive agents such as MTX or
cyclosporine, the synergetic effect of TNF-alfa
inhibitors and conventional immune modulators
may increase the risk of developing malignancy. As
TNF-alfa inhibitor use becomes more popular, this
case suggests the need for close observation to
identify the potential long-term risks associated
with chronic immune modulation.
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hypersensitivity syndrome
To the Editor: Immature neutrophils in the peripheral
circulation (bandemia) are an infrequently reported
finding in drug hypersensitivity syndrome (DHS).1-3
We report a case of DHSwith bandemia that resolved
after withdrawal of the offending medication and
initiation of prednisolone.
A previously healthy, school-aged girl was
admitted to the hospital with a 2-day history of fever,
facial edema, cervical lymphadenopathy, and a
morbilliform eruption that started on the face and
progressed caudally. The rash and fever developed
after 6 days of trimethoprim-sulfamethoxazole
(TMP-SMX) therapy for an uncomplicated urinary
tract infection. She denied ocular pain, dysphagia,
odynophagia, dysuria, and painful skin. Physical
examination revealed an ill-appearing African
American child with a temperature of 39.98C, mild
tachycardia, and tachypnea. A blanching morbilli-
form eruption was noted on her face, trunk, and
extremities with significant facial edema and sub-
centimeter, nontender cervical lymphadenopathy.
Mucosal surfaces were spared. Laboratory values
are listed in Table I. Blood culture revealed negative
findings, as did repeated urinalysis and urine culture.
Human herpesvirus-6 quantitative polymerase chain
reaction was positive at 300 copies/L. Epstein-Barr
virus serologies showed no evidence of current or
previous infection.
Although the patient’s eosinophils were within
normal reference range upon admission, the constel-
lation of clinical and laboratory findings (morbilli-
form eruption with facial edema, fever, elevated liver
enzymes and creatinine, and atypical lymphocytosis
after administration of TMP-SMX) was suggestive of
DHS. TMP-SMX was immediately discontinued, and
prednisolone (1 mg/kg/d) was initiated, in addition
to acetaminophen and maintenance intravenous
fluids. After 1 day of therapy, her eruption had
improved considerably, with normalization of her
vital signs. Her repeated complete blood cell
count on hospital day 2 demonstrated reduction
of peripheral bands to 3%, normalization of serum
